Key facts
- Artax Biopharma’s last known valuation is $58.0M (May 2022).
- It has raised $51.5M across 8 recorded rounds; the latest was Early Stage VC ($19.0M) in Jul 2024.
- Notable investors include ABI LAB, Advent Life Sciences, Belinda Termeer, Columbus Venture Partners, Dosbio50 — 9 tracked in total.
- Artax Biopharma has filed 10 Form Ds with the SEC since 2013, most recently Jul 2025 ($11.0M sold to 30 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Artax Biopharma
Funding rounds
8 roundsAbout Artax Biopharma
Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. The company's drugs eliminate harmful foreign pathogens while being tolerant of self-tissues and organs that simultaneously allow the body to fight foreign pathogens, enabling doctors to treat both the symptoms and the underlying disease with few side effects.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2013
- Employees
- 11
- Website
- artaxbiopharma.com/
- Ownership
- Privately Held (backing)
Artax Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Artax Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Artax Biopharma in its N-PORT filings yet. We sweep new filings monthly.